Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDRapport Therapeutics, Inc. Common Stock Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.75 | -$0.75 | -$0.75 |
| Q2 2025 | 1 | -$0.84 | -$0.84 | -$0.84 |
| Q3 2025 | 1 | -$0.85 | -$0.85 | -$0.85 |
| Q4 2025 | 1 | -$0.96 | -$0.96 | -$0.96 |
| Q1 2026 | 1 | -$0.96 | -$0.96 | -$0.96 |
| Q2 2026 | 1 | -$0.95 | -$0.95 | -$0.95 |
| Q3 2026 | 1 | -$1.22 | -$1.22 | -$1.22 |
| Q4 2026 | 1 | -$1.25 | -$1.25 | -$1.25 |
Rapport Therapeutics, Inc. Common Stock Earnings Date And Information
Rapport Therapeutics, Inc. Common Stock last posted its earnings results on Tuesday, March 11th, 2025. The company reported $-0.57 earnings per share for the quarter, topping analysts' consensus estimates of $-0.62 by $0.05. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Rapport Therapeutics, Inc. Common Stock has generated $0 earnings per share over the last year ($-0.38 diluted earnings per share) and currently has a price-to-earnings ratio of -4.48. Rapport Therapeutics, Inc. Common Stock has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Rapport Therapeutics, Inc. Common Stock Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/11/2025 | Q4 2024 | -$0.62 | -$0.57 | 0.05 | N/A | $0 |
| 11/07/2024 | Q3 2024 | -$0.57 | -$0.50 | 0.07 | $0 | $0 |
| 08/08/2024 | Q2 2024 | -$0.68 | -$0.50 | 0.18 | $0 | $0 |
| 03/30/2024 | Q1 2024 | N/A | -$0.64 | N/A | N/A | $0 |
| 12/31/2023 | Q4 2023 | N/A | $0.00 | N/A | N/A | $0 |
| 09/30/2023 | Q3 2023 | N/A | -$0.36 | N/A | N/A | $0 |
| 06/28/2023 | Q2 2023 | N/A | -$0.18 | N/A | N/A | $0 |
| 03/30/2023 | Q1 2023 | N/A | -$0.17 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Rapport Therapeutics, Inc. Common Stock Earnings: FAQ's
Rapport Therapeutics, Inc. Common Stock has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based offlast year's report dates.
In the previous quarter, Rapport Therapeutics, Inc. Common Stock (:RAPP) reported $-0.57 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.62 by $0.05.
The conference call for Rapport Therapeutics, Inc. Common Stock's latest earnings report can be listened to online.
The conference call transcript for Rapport Therapeutics, Inc. Common Stock's latest earnings report can be read online.
Rapport Therapeutics, Inc. Common Stock (:RAPP) has a recorded net income of $-78,307,000.Rapport Therapeutics, Inc. Common Stock has generated $-0.38 earnings per share over the last four quarters.
Rapport Therapeutics, Inc. Common Stock (:RAPP) has a price-to-earnings ratio of -4.48 and price/earnings-to-growth ratio is 0.13.